Journal of Alzheimer's disease reportsMay 15, 2025

The relationship between GLP-1 receptor drugs and dementia: a detailed review

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jan 20, 2026

Abstract

Ten studies, including six randomized controlled trials, evaluated the effects of glucagon-like peptide-1 receptor agonists on .

showed cognitive benefits in patients with type 2 diabetes mellitus, regardless of metabolic changes.
In early dementia or Alzheimer's disease, treatment with GLP-1 receptor agonists helped preserve brain metabolism and connectivity.
Cognitive improvements were particularly noticeable in individuals with higher body mass index or obesity.
Some studies indicated neural functional changes through imaging, but consistent alterations in established Alzheimer's disease biomarkers were not found.
Further clinical trials are necessary to assess the effects of GLP-1 receptor agonists on dementia progression and related pathology.

Simplified

Type 2 diabetes mellitus (T2DM) and insulin resistance are associated with an increased risk of and dementia, including Alzheimer's disease (AD). Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for glycemic control, are emerging as neuroprotective agents. This review evaluates the evidence regarding the effects of GLP-1RAs in populations with T2DM-both with and without cognitive impairment, as well as in individuals diagnosed with AD. We conducted a comprehensive literature search and identified ten studies for inclusion: six randomized controlled trials, one prospective open-label study, and three observational studies. GLP-1RAs consistently demonstrated cognitive benefits in patients with T2DM, even in the absence of metabolic improvements. In cases of early dementia or AD, GLP-1RA treatment preserved brain metabolism and connectivity but did not significantly alter amyloid or tau biomarkers. Notably, cognitive improvements were most evident in individuals with higher body mass index (BMI) or obesity. While some studies reported neural functional changes via imaging, direct modifications in established AD biomarkers were not consistently observed. In conclusion, GLP-1RAs may improve cognitive outcomes and brain function, particularly in the early stages of neurodegeneration and among high-risk T2DM populations. Further well-designed clinical trials are needed to evaluate the impacts of GLP-1RAs on both the clinical progression and underlying pathology of dementia.

Key numbers

5 of 10 studies

Cognitive Improvement in T2DM Patients

Studies showing cognitive benefits in patients with T2DM treated with GLP-1RAs.

OR 0.80 (95% CI 0.74–0.88)

Reduced Risk of Dementia

Odds ratio indicating the reduced risk of dementia with GLP-1RAs.

p = 0.04

Cerebral Metabolism Preservation

Significant p-value showing preservation of glucose metabolism in brain regions.

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Funding

Competing interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

PubMed

The relationship between GLP-1 receptor drugs and dementia: a detailed review

Abstract

Key numbers

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief